PuSH - Publikationsserver des Helmholtz Zentrums München

Summerer, I. ; Unger, K. ; Braselmann, H. ; Schuettrumpf, L. ; Maihoefer, C. ; Baumeister, P. ; Kirchner, T.* ; Niyazi, M. ; Sage, E.H.* ; Specht, H.M.* ; Multhoff, G. ; Mörtl, S. ; Belka, C. ; Zitzelsberger, H.

Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients.

Br. J. Cancer 113, 76-82 (2015)
Verlagsversion DOI PMC
Free by publisher
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
BACKGROUND: The prediction of therapy response in head and neck squamous cell cancer (HNSCC) requires biomarkers, which are also a prerequisite for personalised therapy concepts. The current study aimed to identify therapy-responsive microRNAs (miRNAs) in the circulation that can serve as minimally invasive prognostic markers for HNSCC patients undergoing radiotherapy. METHODS: We screened plasma miRNAs in a discovery cohort of HNSCC patients before therapy and after treatment. We further compared the plasma miRNAs of the patients to age- and sex-matched healthy controls. All miRNAs identified as biomarker candidates were then confirmed in an independent validation cohort of HNSCC patients and tested for correlation with the clinical outcome. RESULTS: We identified a signature of eight plasma miRNAs that differentiated significantly (P=0.003) between HNSCC patients and healthy donors. MiR-186-5p demonstrated the highest sensitivity and specificity to classify HNSCC patients and healthy individuals. All therapy-responsive and patient-specific miRNAs in plasma were also detectable in tumour tissues derived from the same patients. High expression of miR-142-3p, miR-186-5p, miR-195-5p, miR-374b-5p and miR-574-3p in the plasma correlated with worse prognosis. CONCLUSIONS: Circulating miR-142-3p, miR-186-5p, miR-195-5p, miR-374b-5p and miR-574-3p represent the most promising markers for prognosis and therapy monitoring in the plasma of HNSCC patients. We found strong evidence that the circulating therapy-responsive miRNAs are tumour related and were able to validate them in an independent cohort of HNSCC patients.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Biomarker ; Circulating Non-coding Rna ; Head And Neck Cancer ; Prognosis ; Radiochemotherapy ; Radiotherapy Outcome; Squamous-cell Carcinoma; Human-papillomavirus; Breast-cancer; Radiation-therapy; Esophageal Cancer; Prostate-cancer; Mirnas; Chemoradiotherapy; Mir-142-3p; Markers
ISSN (print) / ISBN 0007-0920
e-ISSN 1532-1827
Zeitschrift British Journal of Cancer BJC
Quellenangaben Band: 113, Heft: 1, Seiten: 76-82 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) CCG Personalized Radiotherapy in Head and Neck Cancer (KKG-KRT)
Research Unit Radiation Cytogenetics (ZYTO)
Institute of Radiation Medicine (IRM)
Institute of Radiation Biology (ISB)